Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ERBA registration revoked:
https://www.sec.gov/litigation/admin/2020/34-89695.pdf
Whoever is the puppet master of this needs to be in cuffs ASAP
ERBA SEC Suspension for severely delinquent Financials:
https://www.sec.gov/litigation/suspensions/2020/34-89207.pdf
Order:
https://www.sec.gov/litigation/suspensions/2020/34-89207-o.pdf
Admin. Proceeding:
https://www.sec.gov/litigation/admin/2020/34-89208.pdf
ERBA from 8k will bank $21,750,000 dollars ,you kidding me trading .265 now
ERBA .0023/.0025 will run crazy here,~~On June 17, 2019, Diamedix Corporation, a wholly-owned subsidiary of ERBA Diagnostics, Inc., as seller (“ Diamedix ”), entered into a Purchase and Sale Agreement (the “ Agreement ”) with PRH Investments, LLC, as buyer (“ Buyer ”), for the sale of the real property owned by Diamedix located at 2115, 2127, 2140, 2141, 2150, 2160 North Miami Avenue, 2155 NW Miami Court and 38 NW 22 nd Street, in Miami, Florida, and all improvements thereon (collectively, the “ Property ”).
Purchase Price . The purchase price for the Property is $21,750,000 (the “ Purchase Price ”).
ERBA~~Purchase Price . The purchase price for the Property is $21,750,000 (the “ Purchase Price ”).
ERBA~~On June 17, 2019, Diamedix Corporation, a wholly-owned subsidiary of ERBA Diagnostics, Inc., as seller (“ Diamedix ”), entered into a Purchase and Sale Agreement (the “ Agreement ”) with PRH Investments, LLC, as buyer (“ Buyer ”), for the sale of the real property owned by Diamedix located at 2115, 2127, 2140, 2141, 2150, 2160 North Miami Avenue, 2155 NW Miami Court and 38 NW 22 nd Street, in Miami, Florida, and all improvements thereon (collectively, the “ Property ”).
Purchase Price . The purchase price for the Property is $21,750,000 (the “ Purchase Price ”).
ERBA~~HUGEEE 8K Item 1.01 Entry into a Material Definitive Agreement.
On June 17, 2019, Diamedix Corporation, a wholly-owned subsidiary of ERBA Diagnostics, Inc., as seller (“ Diamedix ”), entered into a Purchase and Sale Agreement (the “ Agreement ”) with PRH Investments, LLC, as buyer (“ Buyer ”), for the sale of the real property owned by Diamedix located at 2115, 2127, 2140, 2141, 2150, 2160 North Miami Avenue, 2155 NW Miami Court and 38 NW 22 nd Street, in Miami, Florida, and all improvements thereon (collectively, the “ Property ”).
Purchase Price . The purchase price for the Property is $21,750,000 (the “ Purchase Price ”).
Survey Review Period . The Agreement provides a 14 day survey period (the “ Survey Review Period ”) during which Buyer has the right to review a current ALTA/NSPS survey of the Property and confirm the square footage of the Property. If the Survey reflects that the Property contains less than a certain square footage, then Buyer may terminate the Agreement by providing written notice on or before expiration of the Survey Review Period (such notice, the “ Survey Termination Notice ”). To the extent that the Agreement is not terminated prior to the expiration of the Survey Review Period, Buyer has the right to record a Memorandum of Contract against the Property pursuant to which third parties are put on notice of the existence of the Agreement and Buyer is given the right to record a claim of lien against the Property if Diamedix fails to return the Earnest Money (or any portion thereof) as required pursuant to the Agreement.
Examination Period . The Agreement provides for a 60 day examination period (the “ Examination Period ”) during which Buyer has the right to conduct a due diligence investigation of the Property and terminate the Agreement in its sole and absolute discretion. While the Agreement is binding upon Diamedix, Buyer, in its sole and absolute discretion, may terminate the Agreement during the Examination Period.
Anticipated Closing Date . The Agreement provides for the consummation of the purchase and sale of the Property to occur within 60 days after the expiration of the Examination Period.
Earnest Money . Upon entering into the Agreement, Buyer will place into escrow the sum of $100,000 (the “ Initial Earnest Money Deposit ”), and, upon the expiration of the Examination Period, Buyer will deliver to Diamedix the sum of $400,000 (the “ Additional Earnest Money Deposit ,” together with the Initial Earnest Money Deposit, collectively, the “ Earnest Money ”). If Buyer terminates the Agreement during the Survey Review Period by providing a Survey Termination Notice, then the Initial Earnest Money Deposit will be returned to Buyer. If the Survey reflects that the Property contains more than a certain square footage or if Buyer fails to timely deliver a Survey Termination Notice prior to the expiration of the Survey Review Period, then the Escrow Agent will deliver to Diamedix the Initial Earnest Money Deposit. If Buyer terminates the Agreement after the expiration of the Survey Review Period, but prior to the expiration of the Examination Period, then the Initial Earnest Money Deposit will be retained by Diamedix. Once any portion of the Earnest Money is delivered to Diamedix, Diamedix is not required to hold the Earnest Money in escrow and such Earnest Money may be utilized by Diamedix for any purpose and without restriction, subject however, to Diamedix’s obligation to return the Earnest Money following a termination of the Agreement pursuant to certain terms of the Agreement.
Defaults . In the event of a default under the Agreement by Buyer, Diamedix would be entitled to terminate the Agreement and retain the Earnest Money as its sole remedy. In the event of a default under the Agreement by Diamedix, Buyer would be entitled to: (i) terminate the Agreement and receive a refund of the Initial Earnest Money Deposit and/or Additional Earnest Money Deposit, as applicable, together with a reimbursement from Diamedix of Buyer’s documented third party transaction costs and expenses up to $75,000; (ii) attempt to specifically enforce the performance by Diamedix of its obligations under the Agreement; or (iii) only if the remedy of specific performance is not available to Buyer as a result of an intentional act on the part of Diamedix, then Buyer may pursue an action against Diamedix for Buyer’s actual damages.
Reimbursement of Certain Costs . In connection with the demolition of certain improvements located on the Property in accordance with the terms of the Agreement, Buyer has agreed to reimburse Diamedix for any costs and/or expenses incurred by Diamedix in connection with such demolition in excess of $100,000.
Assignment . The Agreement may be assigned by Buyer to any entity in which Buyer or its principals have a controlling interest without the consent of Diamedix.
Certain Other Provisions . The Agreement contains other representations, warranties, conditions, covenants and agreements that the Company believes are customary for transactions of this type.
The foregoing description of the Agreement set forth under this Item 1.01 does not purport to be complete. Such description is only a summary and is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated into this Item 1.01 in its entirety.
As of March 31, 2019, the net book value of the land, buildings and improvements being sold was $352,957.
Safe Harbor Statement
Except for the historical matters contained herein, statements in this Current Report on Form 8-K are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be preceded by, followed by or otherwise include the words “may,” “will,” “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “projects,” “could,” “would,” “should,” or similar expressions or statements that certain events or conditions may occur. These forward-looking statements are based largely on ERBA Diagnostics, Inc.’s expectations and the beliefs and assumptions of ERBA Diagnostics, Inc.’s management and on the information currently available to it and are subject to a number of risks and uncertainties, including, but not limited to, the risks and uncertainties that:
?
Buyer may terminate the Agreement during the 14 day Survey Review Period;
?
Buyer, in its sole and absolute discretion, may terminate the Agreement during the 60 day Examination Period;
?
the consummation of the purchase and sale of the Property may not occur when anticipated, or at all; and
?
other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements.
Many of these factors are beyond the control of ERBA Diagnostics, Inc. See also the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC for further discussion of certain risks and uncertainties that could materially and adversely affect the Company’s business, operating results or financial condition.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibit 10.1 – Purchase and Sale Agreement, dated as of June 17, 2019, by and between Diamedix Corporation and PRH Investments, LLC.
ERBA Balance Sheet
June 30, 2015. Stockholders' Equity > $16,484,472
OS was 44,086,009 as of August 4, 2015. Current pps is 25 cents.
That gives ERBA a market cap of $11,021,502. That's 2/3rds the Stockholders' Equity (total assets - total liabilities).
Revenues are around $24 million per year...lost $505,178 for that Q.
Need to file. What the hell's wrong with them?
Link > ERBA 10Q PERIOD ENDING JUNE 30, 2015
Yes it got delisted too
Dang.
Company has received written and verbal proposals from various potential successor firms, which proposals generally estimate a timeframe of approximately four to eight months to complete the work to allow the Company to file the Reports and the prior financial statements that the Company has previously reported its intention to restate.
Accordingly, the Company has determined that it will not be able to file the Reports and regain compliance with the continued listing standards of the Company Guide by November 25, 2016.
ERB changed to ERBA. Delisted from the AMEX to the OTC:
http://otce.finra.org/DLAdditions
Out no volume at all. Should go up once the Ceo decides to be current with filings etc glta
Anyways the diagnostic sector is consolidating co I work for just bought a diagnostic co for 4billion a week ago or two and the yesterday a diagnostic co I follow hit 52 week high. From a chart perspective erb hit 52 week lows twice this last time on high volume pop. This should be the last low for now. It seems to be consolidating the recent pop and move upwards hopefully the co brings out some news etc. the co is real and a x coworker that worked with me works there at erb
There's not much of a discussion
I followed the Yahoo message board for years.
Went back over 7 months and you have not posted once on this stock.
Wouldn't bank on that. If they do ever get to report, it might be disastrous.
Who knows.
That day days ago on 200k volume how much it went up?
It's sporadic but it takes a few days to go up quickly. It's been quiet for a year
Has the volume been this low is this normal
Triple down this x it's bottom
Too long
2-3 years
How long you been in this stock
Can you please ask them why are they so retarded with there reporting.
Thanks
I'm a block away from office perhaps I should knock knock on they door lol
I sent an email to investor relations no reply. They are a year behind in filings
Too lazy right now for DD. Can anyone else substantiate these claims/facts?
I think ERBA is on the cusp of growth . They are just 3 year old compny with big plans on acquisition and merger. Strong back up by Suresh an entrepreneur the 82% owner of this company. Lots of global spread and incresing account receivables. They need to work on account receivables. Mohan the CEO said in the OneMed their focus will be more on US growth in 2015. Time horizon for merger and folding of all global ERBA units(currently $200M rev) in the next 3 to 5 years. US sales target of $100 to 150 M in the next 3 to 5 years. Consistent profitability is their motto. Immunology and molecular technology appears to be their next target segment. Good source for consistent revenue. Acquisitions in Latin America (Brazil). The best part is the exponential growth on the reagents sales Y over Y. They are planning to grow by selling their instruments cheaply.The new marketing guy seems to have lots of experience. They can become a $500M(Mohan says 1Billion) rev company in 5 years with the added dilution and a total of say 100 million shares .I based it on purchase of all private ERBAs 20% of the $200 revenue+ inventories at a $5 value). If the profits keep growing with increasing margins and consolidation I would guess the stock price will be $15 or more easily in 5 years (based on 3x 500M revenue market cap). Any other meaningful thoughts ?
Overreaction ?
Any thoughts anyone ? Somebody ?
All I here is crickets...
One med video
http://www.onemedmarket.com/#!erba-diagnostics/c20lo
deja vu here ;)....Have you been able to see to the Mohan video presentation from the OneMed conference last week? The file
keeps coming up corrupt for me, as I would really like to listen
for the growth guidance.
http://www.b2i.us/profiles/investor/CSummary.asp?BzID=2247&Nav=0&LangID=1&s=0&tPName=Profile
WAKE UP ;)......ERB will report its third quarter 2014 financial results Monday, November 10, 2014 at approximately 7:30 a.m. Eastern Time. ERBA Chief Executive Officer Mohan Gopalkrishnan, will host a management conference call at 9:00 a.m. Eastern Time to discuss the financial results and business developments.
ERBA Diagnostics Schedules Conference Call to Discuss 2014 Second Quarter Financial Results
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, announced today it will host an earnings call to discuss the Company's second quarter 2014 financial results at 9:00 a.m. EDT (8:00 a.m. CDT) on Tuesday, August 12, 2014.
http://finance.yahoo.com/news/erba-diagnostics-schedules-conference-call-213105973.html
Erba Diagnostics Video Presentation July 24th 2014
We should be getting some play here $$$$OON...Status update from the AACC,and Earnings in next couple of weeks and more importantly....VOLUME
ERB 2.58....You still in cyber?
Ya better load the boat here!
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
161
|
Created
|
11/24/09
|
Type
|
Free
|
Moderators |
http://www.ivaxdiagnostics.com/index.html
http://finance.yahoo.com/q/ks?s=IVD+Key+Statistics
IVAX Diagnostics, Inc. is headquartered in Miami, Florida and develops, manufactures and markets proprietary diagnostic reagents, instrumentation and software worldwide through its three subsidiaries; Diamedix Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc.
IVAX Diagnostics, Inc. was created as a result of the merger on March 14, 2001 between b2bstores.com, Inc. and the diagnostic business subsidiary within IVAX Corporation. On January 26, 2006 , IVAX Corporation was merged into a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (Teva). As a result of this merger, Teva, indirectly through its IVAX Corporation subsidiary, owned approximately 72% of IVAX Diagnostics. On September 2, 2008 , a group controlled by two experienced and well-known international medical diagnostics and pharmaceutical industry entrepreneurs, Paul Kennedy and Patrice Debregeas, purchased all of the shares of IVAX Diagnostics' common stock owned by Teva and, accordingly, collectively owns approximately 72% of IVAX Diagnostics. On September 1, 2010, ERBA Diagnostics Mannheim GmbH, an in vitro diagnostics company headquartered in Germany (ERBA), purchased all of the approximately 72% of the outstanding shares of the Company's common stock owned by the group controlled by Messrs. Debregeas and Kennedy. As a result of the share acquisition, ERBA now owns approximately 72.5% of the outstanding shares of the Company's common stock.
IVAX Diagnostics' common stock trades under the ticker symbol IVD on the American Stock Exchange.
Diamedix Corporation develops and manufactures in vitro diagnostics kits that it markets in conjunction with its MAGO® Plus instruments for use in clinical and hospital laboratories.
ImmunoVision, Inc. develops manufactures and markets autoimmune reagents and research products for use in clinical laboratories, research laboratories and other diagnostic manufacturing companies.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |